Q-omics provides the consensus-scored DUS1L profile across patient tissues and cancer cell-line models. DUS1L expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DUS1L is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, DUS1L RNA expression shows 18,763 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, BLCA, and ACC as cancer lineages where DUS1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUS1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUS1L survival associations across molecular data types. DUS1L RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUS1L RNA expression–survival associations across cancer types. High DUS1L expression shows unfavorable associations in KIRC, ACC, UVM, LGG, MESO and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DUS1L RNA expression.
This table summarizes DUS1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for DUS1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUS1L shows higher tumor expression in BLCA, COAD, KIRP, LIHC, LUAD and STAD. The BLCA box plot shows higher DUS1L RNA expression in tumor versus normal tissue (log2 FC = +1.224, t-test p < 0.001).
This table shows molecular features associated with DUS1L in patient tissues and cancer cell lines. In patient samples, DUS1L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DUS1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
